Tumor immunology has changed the landscape of cancer treatment. Yet, not all patients
benefit as cancer immune responsiveness (CIR) remains a limitation in a considerable …

TIGIT, an immune checkpoint molecule widely expressed on NK cells, activated T cells and
Tregs, has been involved in delivering inhibitory signals through the interaction with PVR …

Background DNA mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC) is
not responsive to pembrolizumab monotherapy. DNA methyltransferase inhibitors can …

Abstract Background Long noncoding RNAs (lncRNAs) are emerging as critical regulatory
elements and play fundamental roles in the biology of various cancers. However, we are still …

Mutations in APC promote colorectal cancer (CRC) progression through uncontrolled WNT
signaling. Patients with desmoplastic CRC have a significantly worse prognosis and do not …

The combined administration of programmed cell death 1 (PD-1) and programmed cell
death ligand 1 (PD-L1) inhibitors might be considered as a treatment for poorly responsive …

In recent years, restoring anti-tumor immunity has garnered a growing interest in cancer
treatment. As potential therapeutics, immune checkpoint inhibitors have demonstrated …

Background: Immunotherapy has changed the options for the treatment of various cancer
types, but not colon cancer. Current checkpoint blockade approaches are ineffective in a …

Topoisomerase inhibitors are clinically used to treat various cancer types, including
colorectal cancer. These drugs also activate signaling pathways that modulate cell survival …

We thank Dr. Yang and colleagues for their discussion and Letter to the Editor regarding our
manuscript “Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with …